Publications

Use of {BTK} inhibitors with special focus on ibrutinib in Waldenström macroglobulinemia: An expert panel opinion statement  (2022)

Authors:
Ferrero, S.; Gentile, Massimo; Laurenti, Luca; Romana Mauro, Francesca; Martelli, Maurizio; Sportoletti, Paolo; Visco, Carlo; Luigi Zinzani, Pier; Tedeschi, Alessandra; Varettoni, M.
Title:
Use of {BTK} inhibitors with special focus on ibrutinib in Waldenström macroglobulinemia: An expert panel opinion statement
Year:
2022
Type of item:
Articolo in Rivista
Tipologia ANVUR:
Articolo su rivista
Language:
Inglese
Referee:
No
Name of journal:
Hematological Oncology
ISSN of journal:
0278-0232
Page numbers:
1382-1386
Keyword:
BTK inhibitors; Waldenström macroglobulinemia; ibrutinib; real-world; recommendations
Short description of contents:
: The pivotal role that ibrutinib plays in the management of Waldenström macroglobulinemia (WM) is undisputed but there are ongoing questions regarding its positioning in the therapeutic algorithm of WM as well as in some peculiar clinical situations. A panel of experts from Italy was convened to provide real world recommendations on the use of BTK inhibitors in lymphoproliferative diseases in general, and in patients with WM in particular. This position paper represents the panel's collective analysis, evaluation, and opinions and is made up of a series of questions frequently asked by practicing clinicians and answers based on currently available evidence.
Product ID:
126846
Handle IRIS:
11562/1064969
Last Modified:
December 20, 2024
Bibliographic citation:
Ferrero, S.; Gentile, Massimo; Laurenti, Luca; Romana Mauro, Francesca; Martelli, Maurizio; Sportoletti, Paolo; Visco, Carlo; Luigi Zinzani, Pier; Tedeschi, Alessandra; Varettoni, M., Use of {BTK} inhibitors with special focus on ibrutinib in Waldenström macroglobulinemia: An expert panel opinion statement «Hematological Oncology»2022pp. 1382-1386

Consulta la scheda completa presente nel repository istituzionale della Ricerca di Ateneo IRIS

<<back
Share